# Brii Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brii-biosciences

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.briibio.com
- Total disclosed funding: $24M
- Latest round: Series C (Mar 23, 2021)
- Investors on record: 3

## About

Brii Biosciences Limited, established in 2018 and based in Beijing, China, focuses on developing innovative treatment options for infectious diseases, notably targeting chronic conditions like Hepatitis B and HIV.Brii Biosciences Limited specializes in infectious disease treatments, with a headquarters in Beijing, China. Founded by Zhi Hong, the company raised HKD 2.48 billion in an IPO in July 2021. The firm has completed three deals, all leading to its latest funding round, the IPO, which provided total funding of HKD 2.48 billion. Chloe Jiang serves as the CEO.Brii Biosciences specializes in developing innovative treatment options for infectious diseases, primarily addressing unmet medical needs associated with chronic conditions such as Hepatitis B and HIV. Their core product offerings include BRII-179, a treatment aimed at achieving higher HBsAg loss in patients with chronic Hepatitis B, and various novel therapeutic candidates designed for HIV. The products are engineered to provide first-in-class or different-in-class solutions, thereby enhancing treatment efficacy and patient outcomes where traditional options are limited. These treatment options target patient populations that often face social stigmas and inadequate access to care, significantly focusing on regions such as China and other international markets where the burden of infectious diseases is pronounced. By leveraging breakthrough scientific innovations, Brii Biosciences aims to improve the quality of life for patients globally.Brii Biosciences generates revenue primarily through partnerships with healthcare providers and pharmaceutical distributors that facilitate the commercialization of its therapeutic products. The company engages in B2B transactions, collaborating with clinical research organizations and healthcare systems to promote its offerings, including flagship products like BRII-179. Revenue is structured around product sales and contractual agreements that may include milestone payments linked to clinical trial progress or regulatory approvals. Their clinical data presentations and updates reflect ongoing efforts to secure market access and expand the utilization of their treatments in key markets. The precise pricing plans for these products are aligned with their developmental and therapeutic value, reinforcing Brii Biosciences’ commitment to addressing public health challenges through effective and sustainable treatment solutions.Brii Biosciences plans to utilize its recent funding of HKD 2.48 billion from the IPO to advance its infectious disease project pipeline and expand its portfolio in central nervous system diseases. The company aims to introduce new therapeutic candidates targeting unmet medical needs within the next few years, with a particular focus on markets in Asia and beyond. Their strategy includes enhancing access to treatments in regions with high burdens of infectious diseases, leveraging the strategic funding to ensure efficient development and commercialization of their innovative solutions.

## Funding rounds

- Series C, Mar 23, 2021, $24M — Invesco, GIC, Lake Bleu Capital

## Investors

- Invesco (https://capitalatlas.ai/funds/invesco) — Series C
- GIC — Series C
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series C